0 results

Patient Corner

Anatomical Illustrations

More

Latest drug updates

  • 28 Apr 2017 - Drug Updates

Ponatinib (Iclusig▼): Risk of vascular arterial occlusion is dose-dependent

Dose reduction of ponatinib to 15 mg a day can decrease the risk of vascular arterial occlusion.

Read more
  • 28 Apr 2017 - Drug Updates

Valproate (Epilim▼, Depakote▼): High risk of neurodevelopmental disability and birth defects

Valproate should not be prescribed to women and girls of childbearing potential unless other treatments are ineffective or not tolerated.

Read more
  • 28 Apr 2017 - Drug Updates

Multiple sclerosis: Rebound syndrome after stopping fingolimod (Gilenya▼) or switching therapy

HCPs advised to report adverse effects associated with fingolimod (Gilenya▼) or other treatments for multiple sclerosis.

Read more
  • 23 Mar 2017 - Drug Updates

Canagliflozin (Invokana▼): Increased risk of lower limb amputation

Close monitoring in patients with uncontrolled diabetes and comorbidities like heart and blood vessel events.

Read more
  • 23 Mar 2017 - Drug Updates

Pilot website to report adverse reactions of psychoactive substances

Illicit drug reaction reporting form made available for healthcare professionals,

Read more
  • 8 Mar 2017 - Drug Updates

Hyoscine butylbromide: serious adverse effects in cardiac patients

9 fatalities have been reported so far.

Read more
  • 24 Jan 2017 - Drug Updates

Apremilast (Otezla▼): risk of psychiatric symptoms

Increased risk for depression and suicidality in apremilast users.

Read more
  • 23 Jan 2017 - Drug Updates

Direct-acting antivirals for chronic HCV (interferon-free): risk of hepatitis B reactivation

Co-infected patients require close monitoring.

Read more
  • 23 Jan 2017 - Drug Updates

Direct-acting antivirals for HCV and vitamin K antagonists: risk of interaction

INR monitoring required in patients on concurrent drug therapy.

Read more
  • 19 Apr 2016 - Drug Updates

Drug safety alert: Risk of diabetic ketoacidosis with SGLT2 inhibitors

Patients receiving SGLT2 inhibitors with ketoacidosis symptoms should be tested for raised ketones, even if plasma glucose levels are near-normal.

Read more